

CORRESPONDENCE

Functional HRD by RAD51 identifies *BRCA1* VUS associated with loss of gene function and response to DNA-damaging agents



Almost 15% of patients with breast and high-grade serous ovarian cancer (HGSOC) undergoing germline genetic testing harbor variants of uncertain significance (VUS) in *BRCA1* and *BRCA2* genes.¹ VUS represent a challenge both for risk assessment and prediction of response to treatments. Tools to assess the functional impact of VUS are needed to evaluate their predictive role of response to DNA-damaging agents.

RAD51 assay is a functional and dynamic test carried out on tumor tissue which reflects the homologous recombination repair (HRR) status.^{2,3} The assay tests the immunofluorescence of γ H2AX as sensor of double-strand break DNA damage, *BRCA1* as one of the main HRR mediators, and RAD51 as HRR final effector. When HRR is proficiently activated, RAD51 forms nuclear foci, identifying the HRR-proficient (HRP) status⁴; the absence of nuclear foci identifies the HRR-deficient (HRD) status. We carried out RAD51 assay on tumor samples from three patients harboring the germline VUS c.4096+1G>A,⁵ in heterozygous state, in *BRCA1* gene and treated with platinum-based chemotherapy and/or poly(adenosine diphosphate—ribose) polymerase (PARP) inhibitors (PARPi). All patients were tested for the presence of germline pathogenic variants in *BRCA1/2* and low penetrance genes, and somatic mutations in *BRCA1/2*, using next-generation sequencing on blood and tumor samples, respectively.⁶ No germline pathogenic mutations were detected in the other genes.

The clinical history of the three patients is briefly reported:

- Patient number 1, 66-year-old, diagnosed with HGSOC, underwent surgery, first-line chemotherapy with carboplatin plus paclitaxel and maintenance treatment with bevacizumab. After 2 years, she relapsed and was treated with carboplatin plus gemcitabine with rapid progression of disease (PD).
- Patient number 2, 42-year-old, daughter of patient number 1, diagnosed with metastatic breast cancer, was treated with carboplatin with a rapid PD. She subsequently received olaparib through off-label use, with no response and PD.
- Patient number 3, 37-year-old, diagnosed with HGSOC, underwent chemotherapy with carboplatin plus paclitaxel in a perioperative setting with interval debulking surgery, obtaining pathological complete response. She started niraparib maintenance therapy and is currently progression-free after 3 years.

RAD51 assay was carried out on tumor samples collected before carboplatin treatment (Figure 1):

- Patient number 1: *BRCA1* and RAD51 foci were detected, classifying sample as HRP.
- Patient number 2: *BRCA1* and RAD51 foci were detected, classifying sample as HRP.
- Patient number 3: *BRCA1* and RAD51 foci were absent, classifying sample as HRD.

To characterize the zygosity status on tissue samples, the germline variant *BRCA1* c.4096+1G>A was tested in the same tissue biopsy studied for RAD51 assay. All patients presented the VUS at variant allele frequency (VAF) consistent with a homozygous state (with a range of 94%–95.8%), suggesting loss of heterozygosity as a possible second hit.

In our case series, the only patient harboring *BRCA1* VUS and showing *BRCA1* loss of function and HRD status according to RAD51 assay obtained a remarkable and durable response to carboplatin/PARPi.

Based on our results, we may speculate that RAD51 assay could successfully predict response to DNA-damaging therapies in patients harboring the VUS c.4096+1G>A in *BRCA1* gene. Our work has some limitations: patients' clinical settings are different and do not permit a direct comparison of response to platinum salts and/or PARPi; furthermore, we cannot exclude that HRD status could be related with other mechanisms independent from VUS (e.g. *BRCA1* promoter methylation).

The potential predictive role of RAD51 assay in patients with VUS in *BRCA1/2* and other HRR genes should be investigated in a wider population.

C. Casartelli^{1,2,3,†}, C. Tommasi^{1,2,3,†}, A. Lazzarin^{1,2,3,†}, M. Coriano^{1,2,3}, C. Tornali¹, O. Serra^{1,2,3}, N. Campanini⁴, S. Gutiérrez-Enríquez⁵, A. Sikokis^{2,3}, D. Zanoni^{2,3}, R. Minari², B. Bortesi², M. Michiara^{2,3}, D. Boggiani^{2,3}, V. Uliana⁶, A. Llop-Guevara⁷, V. Serra^{7,†}, A. Musolino^{1,2,3,*†} & B. Pellegrino^{1,2,3,†}

¹Department of Medicine and Surgery, University of Parma, Parma, Italy; ²Medical Oncology Unit, University Hospital of Parma, Parma, Italy; ³Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy; ⁴Pathology Unit, University Hospital of Parma, Parma, Italy; ⁵Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ⁶Medical Genetics Unit, University Hospital of Parma, Parma, Italy; ⁷Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(*E-mail: antonino.musolino@unipr.it).




Figure 1. Graphical abstract of the results.

BC, breast cancer; HRD, homologous recombination repair-deficient; HRP, homologous recombination repair-proficient; OC, ovarian cancer; pCR, pathological complete response; PD, progression of disease; Pt., patient; RC, complete response

[†]These authors contributed equally to this work.

[‡]Co-last authors.

Available online 5 July 2024

© 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.esmoop.2024.103629>

FUNDING

This work was supported by European Society for Medical Oncology to BP (no grant number) and ERA-NET Cofund [ERAPERMED 2019–215 to VS].

DISCLOSURE

SGE is supported by the Spanish Instituto de Salud Carlos III funding, grants PI19/01303 and PI22/01200 and the Government of Catalonia. VS and ALG report a patent for PCT/EP2018/086759 pending. VS reports grants and personal fees from AstraZeneca. BP reports grants from Roche; other support from Pfizer, Lilly, Gilead, and Novartis; and personal fees from Merck. Member of advisory board for Daiichi-

Sankyo. AM is member of advisory board of AstraZeneca, Gilead, Lilly, Novartis, Roche, and Seagen, he received speakers' bureau from Amgen, Sanofi, Merck Sharpe & Dohme (MSD), Eisai, AstraZeneca, Merck, Bayer and had contracted research with Lilly and Roche. All other authors have declared no conflict of interest.

REFERENCES

1. Yadav S, Ladkany R, Yadav D, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. *Clin Breast Cancer*. 2018;18(5):e1229-e1235.
2. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. *EMBO Mol Med*. 2018;10:e9172.
3. Pellegrino B, Herencia-Roper A, Llop-Guevar A, et al. Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification. *Cancer Res*. 2022;82(8):1646-1657.
4. Duran-Lozano L, Montalban G, Bonache S, et al. Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T. *Breast Cancer Res Treat*. 2019;174(2):543-550.
5. ClinVar. Available at: <https://preview.ncbi.nlm.nih.gov/clinvar/variation/37565/>. Accessed May 17, 2024.
6. SOPHiA DDMTM Dx Hereditary Cancer Solution. Available at: <https://www.sophiagenetics.com/clinical/oncology/hereditary-cancers/sophia-ddm-dx-hereditary-cancer-solution-hcs/> Accessed May 17, 2024.